Friday, December 5, 2025, Orlando, Florida, 11:30 AM – 1:30 PM Eastern Time
Cases from the Community: Investigators Discuss Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia
A CME-Accredited Friday Satellite Symposium Preceding the 67th ASH Annual Meeting
Event Details
Download Webinar Slides
Download Slides (PDF) Download Slides (PPT)
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
Location
Hyatt Regency Orlando
9801 International Drive
Orlando, Florida
Meeting Room
Regency Ballroom TUV (Convention Level)
Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
Stanford University School of Medicine
Stanford, California
Professor Constantine Tam, MBBS, MD
Head of Lymphoma Service
Alfred Health
Professor of Haematology
Monash University
Melbourne, Australia
Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.
Agenda
11:00 AM – 11:30 AM — Registration and Lunch
11:30 AM – 1:30 PM — Educational Meeting
MODULE 1: Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids
- Clinical, biological and practical factors influencing front-line therapeutic selection for patients with CLL
- Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve and relapsed/refractory (R/R) CLL; application in up-front decision-making
- Key efficacy and safety data with venetoclax-based up-front treatment for CLL
- Published findings from the Phase III AMPLIFY trial of fixed-duration acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated CLL
- Early data with zanubrutinib in combination with Bcl-2 inhibitors, such as venetoclax and sonrotoclax, with or without an anti-CD20 antibody for treatment-naïve CLL
- Current role, if any, of novel doublet and triplet combinations in therapy for patients with previously untreated CLL; ongoing Phase III studies
MODULE 2: Optimal Management of Adverse Events (AEs) with Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Prof Tam
- Relevant patient comorbidities, such as hypertension, preexisting cardiac arrhythmias, chronic kidney disease and chronic migraines, and concomitant medications that may influence the choice of therapy for CLL
- Spectrum, frequency and severity of cardiovascular AEs with BTK inhibitors; optimal monitoring and management protocols
- Incidence and management of noncardiovascular AEs associated with various BTK inhibitors
- Frequency of tumor lysis syndrome with venetoclax for CLL; monitoring, prophylaxis and management protocols
- Recommended approaches to identify and manage other common AEs reported with venetoclax, such as cytopenias, infections and gastrointestinal disorders
- Incidence, severity and management of clinically relevant toxicities encountered when combining BTK and Bcl-2 inhibitors with or without anti-CD20 antibodies
MODULE 3: Selection and Sequencing of Therapy for R/R CLL — Dr Woyach
- Clinical and biological factors guiding decision-making for patients with R/R CLL; current role of rechallenge with an agent or class of agents received in a prior line of therapy
- Mechanistic similarities and differences between noncovalent and covalent BTK inhibitors; implications for efficacy and tolerability
- Published findings from key trials, such as BRUIN and BRUIN CLL-321, supporting the use of pirtobrutinib for patients with R/R CLL
- Emerging data from the Phase III BRUIN CLL-313 trial comparing pirtobrutinib to bendamustine/rituximab for previously untreated CLL
- Emerging positive results from the Phase III BRUIN CLL-314 trial comparing pirtobrutinib to ibrutinib for patients with CLL, including those with treatment-naïve disease
- Potential clinical role of pirtobrutinib in treatment for newly diagnosed CLL
- Spectrum, frequency and severity of toxicities with pirtobrutinib relative to covalent BTK inhibitors
- Similarities and differences between pirtobrutinib and nemtabrutinib; early efficacy and safety data with nemtabrutinib for R/R CLL and ongoing Phase III evaluation for R/R and treatment-naïve disease
MODULE 4: Chimeric Antigen Receptor (CAR) T-Cell Therapy and Other Novel Strategies for CLL — Dr Fakhri
- Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial
- FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection
- Early findings with other CAR T-cell-based approaches, such as liso-cel in combination with ibrutinib, for heavily pretreated CLL
- Biological rationale for the investigation of bispecific antibodies for patients with R/R CLL
- Antitumor activity and safety documented with epcoritamab for R/R CLL and CLL with Richter’s syndrome in the Phase Ib/II EPCORE CLL-1 study
- Mechanistic similarities and differences between BTK degraders and BTK inhibitors; implications for the efficacy of these strategies for patients with BTK resistance mutations
- Updated safety and efficacy findings with the BTK degrader catadegbrutinib (BGB-16673) for patients with heavily pretreated CLL in the Phase I CaDAnCe-101 study; FDA fast track designation and potential clinical role
- Other promising agents and strategies under investigation for CLL
CE Information
Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).
Learning Objectives
Upon completion of this activity, participants should be able to
- Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and preferences for time-limited or continuous treatment.
- Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
- Evaluate available and emerging Phase III data demonstrating the efficacy of covalent and noncovalent BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
- Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL, and counsel patients regarding the risks and benefits of this novel treatment strategy.
- Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with CLL.
- Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for relapsed/refractory CLL, and use this information to identify patients appropriate for treatment with these agents.
- Evaluate the biological rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy for CLL, and identify patients for whom treatment with this novel therapeutic strategy would be appropriate.
- Implement a plan of care to recognize and manage side effects and toxicities associated with available systemic therapies commonly employed in the treatment of CLL.
- Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL, and as applicable, refer eligible patients for clinical trial participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Prof Tam has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Davids — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger, Takeda Pharmaceuticals USA Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, MEI Pharma Inc, Novartis; Nonrelevant Financial Relationships: UpToDate. Dr Fakhri — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, BeOne, Genmab US Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company. Dr Woyach — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Newave, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Karyopharm Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MingSight Pharmaceuticals, MorphoSys, Schrödinger, Verastem Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Lilly.
Location
Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
+1 407 284 1234
Meeting Room
Regency Ballroom TUV (Convention Level)
Directions
The Hyatt Regency Orlando hotel is connected by pedestrian bridges to the Orange County Convention Center, where the ASH Annual Meeting is taking place.
Registration
There is no registration fee for this event. For the in-person symposium in Orlando, preregistration (below) is required as seating is limited for this program.
NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.